UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

URGN has been the topic of several other research reports. Scotiabank began coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of UroGen Pharma in a research report on Monday. The Goldman Sachs Group dropped their price objective on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Finally, LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, UroGen Pharma presently has a consensus rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $11.64 on Monday. The firm has a market cap of $536.53 million, a PE ratio of -3.70 and a beta of 0.80. UroGen Pharma has a fifty-two week low of $8.94 and a fifty-two week high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business has a 50 day moving average price of $10.47 and a 200-day moving average price of $11.08.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Equities research analysts predict that UroGen Pharma will post -3.12 earnings per share for the current year.

Insider Activity at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Barclays PLC grew its stake in UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after buying an additional 48,040 shares during the last quarter. Geode Capital Management LLC grew its position in UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after buying an additional 34,248 shares in the last quarter. Tidal Investments LLC grew its position in UroGen Pharma by 19.1% in the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock valued at $477,000 after buying an additional 6,030 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of UroGen Pharma by 263.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after purchasing an additional 49,318 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of UroGen Pharma by 44.1% during the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after purchasing an additional 6,207 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.